search icon
      blog search icon

      Why is the stock of Ziopharm Oncology IN (ZIOP) soaring in aftermarket? - Stocks Telegraph

      By Mahrukh Rehan

      Published on

      September 7, 2021

      7:25 AM UTC

      Why is the stock of Ziopharm Oncology IN (ZIOP) soaring in aftermarket? - Stocks Telegraph

      ZIOP is experiencing an increase of 19.39% in the aftermarket on Friday. However, the normal trading session closed at $0.12 with a decrease of 6.78%.

      Participation in September Investor Conferences by ZIOP

      On 1st September 2021, Kevin S. Boyle, Sr., Ziopharm’s Chief Executive Officer, has announced to participate at 5 forthcoming virtual investor conferences: ZIOP will be taking part in the 2021 Wells Fargo Virtual Health care conference on September 9, 2021, which will be held at 10 a.m. Moreover, Morgan Stanley 19th Annual Global Healthcare Conference will take place on 10th September 2021 and H.C. Wainwright 23rd Annual Global Investment Conference on 13th September 2021.

      Last but not the least, Lake Street 5th Annual Best Ideas Growth Conference will occur on 15th September 2021 and the 2021 Cantor Virtual Global Healthcare Conference will be held on 28 September 2021.

      Ziopharm announces second quarter 2021 corporate updates

      ZIOP announced second-quarter 2021 corporate results on August 9, 2021.

      • The TCR-T Library Clinical Program at the company has made significant progress. The Company has accomplished numerous significant milestones in its TCR-T Program since the last quarterly report. Importantly, the firm is still on schedule to start dosing patients in its Phase I/II TCR-T Library study in the second half of 2021, with the first patient expected to be dosed in the fourth quarter of this year.
      • Some facts were also stated regarding the closing of Silicon Valley Bank’s Venture Debt Financing. The Company announced that it has closed a venture loan arrangement with Silicon Valley Bank for a total of $50 million. The Company will immediately withdraw a $25 million tranche from this facility. A second $25 million tranche will be made available if certain clinical milestones and other requirements are met.
      • Eden BioCell, the Company’s Taiwanese joint venture with TriArm Therapeutics, began treating patients in a clinical trial with the Company’s investigational CD19 RPM CAR-T cell therapy. In the trial, two patients were treated. No significant adverse safety events have been recorded in any of these patients. Moreover, laboratory findings confirm that non-viral Sleeping Beauty gene transfer is efficient in genetically altering autologous T-cells.

      First Quarter 2021 Financial Results

      ZIOP stated the first quarter of 2021 financial results on May 6, 2021. In the first quarter of 2021, research and development expenses were $13.3 million owing to an increase in cell therapy program costs.

      In the first quarter of 2021, general and administrative costs were $8.2 million. Increased employee-related expenses and legal costs connected with its expanding patent portfolio are largely responsible for the increase in general and administrative expenses.

      In the first quarter of 2021, the company lost $21.6 million, unfortunately.

      In addition, the Company has a prepayment of approximately $5.1 million for work to be done at MD Anderson under its research and development agreements.

      More From Stocks telegraph